Publications by authors named "Jacob A Aelion"

Claim this Profile
O
Optimizing oral immune tolerance to Type II collagen in patients with rheumatoid arthritis: The importance of dose, interfering medication and genetics.
Arnold E Postlethwaite, Yan Jiao, Chengyuan Yang, Wei Dong, Jacob A Aelion

Am J Med Sci· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
Laure Gossec, Laura C Coates, Dafna D Gladman, Jacob A Aelion, Jitendra Vasandani

Ann Rheum Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, Paul Bird, Benoit Guerette, Jacob A Aelion

Rheumatology (Oxford)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.
Mark C Genovese, Michael E Weinblatt, Jacob A Aelion, Heikki T Mansikka, Paul M Peloso

Arthritis Rheumatol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
Mark C Genovese, Michael E Weinblatt, Philip J Mease, Jacob A Aelion, Paul M Peloso

Rheumatology (Oxford)· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, Paul Bird, Dianne Nguyen, Jacob A Aelion

Rheumatology (Oxford)· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
Peter Nash, Kamal Ohson, Jessica Walsh, Nikolay Delev, Dianne Nguyen, Jacob A Aelion

Ann Rheum Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
Joachim Sieper, Atul Deodhar, Helena Marzo-Ortega, Jacob A Aelion, Ricardo Blanco

Ann Rheum Dis· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
Mark C Genovese, Patrick Durez, Hanno B Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A Aelion

J Rheumatol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Mark C Genovese, Patrick Durez, Hanno B Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A Aelion

Ann Rheum Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis